• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Novel breast cancer therapeutic strategy by targeting Y-box binding protein 1 activation pathways

Research Project

Project/Area Number 17K15508
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Medical pharmacy
Research InstitutionKyushu University

Principal Investigator

Shibata Tomohiro  九州大学, 薬学研究院, 学術研究員 (40795986)

Project Period (FY) 2017-04-01 – 2019-03-31
Project Status Completed (Fiscal Year 2018)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
KeywordsYB-1 / 乳癌 / 内分泌治療耐性 / ER / HER2
Outline of Final Research Achievements

Despite considerable advances in the treatment of estrogen receptor alpha (ERα)-positive breast cancer, numerous patients develop recurrence during endocrine therapy. Drug resistance to various anticancer drugs is often correlated with enhanced nuclear expression of the Y-box binding protein-1 (YB-1) in breast cancer. In this study, fulvestrant resistant breast cancer cell lines (FR-1 and FR-2) showed markedly reduced expression of ERα and increased expression levels of pYB-1, pmTOR, pAKT, pp70S6K, and pS6. FR-1 and FR-2 showed collateral sensitivity to everolimus (an mTORC1 inhibitor). Furthermore, we demonstrated that pYB-1 directly promoted the ERα-independent cell growth of breast cancer cells. Finally, treatment with everolimus could overcome acquired resistance to antiestrogens through reduction of pYB-1 expression in vivo,
Based on these findings, we concluded that the pYB-1 represents an attractive therapeutic target for endocrine therapy resistant breast cancer.

Academic Significance and Societal Importance of the Research Achievements

ERα陽性乳癌の治療においてERα標的を標的とした内分泌治療の継続による耐性がんの出現が大きな克服すべき課題である。内分泌治療耐性メカニズムには、ERαの活性化変異やERα欠失、バイパスシグナルの活性化などが報告されているが、有効な克服治療は見いだされていない。本研究で、内分泌治療耐性乳癌細胞を駆使した検討から、リン酸化YB-1がERα発現を抑制し、増殖関連遺伝子の発現を上昇させることで、内分泌耐性を誘導することを明らかにした。さらに、YB-1リン酸化標的薬が内分泌治療耐性乳癌の克服に有効であることを明らかにすることができ、今後の研究の発展により乳癌治療の向上に大きく貢献できると考えられる。

Report

(3 results)
  • 2018 Annual Research Report   Final Research Report ( PDF )
  • 2017 Research-status Report
  • Research Products

    (8 results)

All 2019 2018 2017 Other

All Journal Article (2 results) (of which Peer Reviewed: 2 results,  Open Access: 2 results) Presentation (5 results) (of which Int'l Joint Research: 1 results,  Invited: 1 results) Remarks (1 results)

  • [Journal Article] Oncogenic Y‐box binding protein‐1 as an effective therapeutic target in drug‐resistant cancer2019

    • Author(s)
      Kuwano Michihiko、Shibata Tomohiro、Watari Kosuke、Ono Mayumi
    • Journal Title

      Cancer Science

      Volume: 110 Issue: 5 Pages: 1536-1543

    • DOI

      10.1111/cas.14006

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer2018

    • Author(s)
      Shibata Tomohiro、Tokunaga Eriko、Hattori Satoshi、Watari Kosuke、Murakami Yuichi、Yamashita Nami、Oki Eiji、Itou Junji、Toi Masakazu、Maehara Yoshihiko、Kuwano Michihiko、Ono Mayumi
    • Journal Title

      Oncotarget

      Volume: 9 Issue: 98 Pages: 37216-37228

    • DOI

      10.18632/oncotarget.26469

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access
  • [Presentation] Overcoming endocrine therapy resistance by drugs targeting YBX1 activation pathway in breast cancer2019

    • Author(s)
      Tomohiro Shibata, Kosuke Watari, Akihiko Kawahara, Tomoya Sudo, Yuichi Murakami, Eriko Tokunaga, Nami Yamashita, Eiji Oki, Yoshihiko Maehara, Jun Akiba, Yoshito Akagi, Maki Tanaka, Michihiko Kuwano, Mayumi Ono.
    • Organizer
      AACR Annual Meeting 2019
    • Related Report
      2018 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Y-box binding protein YB-1活性化を標的とした乳癌の内分泌治療耐性の克服治療2018

    • Author(s)
      柴田智博, 渡公佑, 河原明彦, 和泉弘人, 村上雄一, 桑野信彦, 小野眞弓
    • Organizer
      第22回日本がん分子標的治療学会学術集会
    • Related Report
      2018 Annual Research Report
  • [Presentation] Y-box binding protein YB-1活性化抑制による乳癌の内分泌治療耐性克服2018

    • Author(s)
      柴田智博、渡公佑、河原明彦、主藤朝也、村上雄一、和泉弘人、秋葉純、桑野信彦、小野眞弓
    • Organizer
      第77回日本癌学会学術総会
    • Related Report
      2018 Annual Research Report
  • [Presentation] ERαとHER2発現のY-box binding protein-1 (YB-1)による制御と乳癌内分泌治療耐性2017

    • Author(s)
      柴田智博、渡公佑、河原明彦、和泉弘人、村上雄一、桑野信彦、小野眞弓
    • Organizer
      第21回日本がん分子標的治療学会学術集会
    • Related Report
      2017 Research-status Report
    • Invited
  • [Presentation] Y-box binding protein YB-1は乳癌のERαとHER2発現を制御して内分泌治療耐性2017

    • Author(s)
      柴田智博、渡公佑、河原明彦、主藤朝也、村上雄一、和泉弘人、伊藤研一、秋葉純、桑野信彦、小野眞弓
    • Organizer
      第76回日本癌学会学術総会
    • Related Report
      2017 Research-status Report
  • [Remarks] 九州大学大学院 薬学研究院 創薬腫瘍科学講座

    • URL

      http://shuyo.phar.kyushu-u.ac.jp/

    • Related Report
      2018 Annual Research Report 2017 Research-status Report

URL: 

Published: 2017-04-28   Modified: 2020-03-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi